Nature of β-Cell Failure Tied to Glycemic Response to GLP-1RA

This article originally appeared here.
Share this content:
Nature of β-Cell Failure Tied to Glycemic Response to GLP-1RA
Nature of β-Cell Failure Tied to Glycemic Response to GLP-1RA

(HealthDay News) -- In patients with type 2 diabetes, characteristics and biomarkers of β-cell failure are associated with glycemic response to GLP-1 receptor agonist (GLP-1RA) therapy, according to a study published online Aug. 4 in Diabetes Care.

Angus G. Jones, M.B.B.S., from the University of Exeter Medical School in the United Kingdom, and colleagues examined whether clinical characteristics and simple biomarkers of β-cell failure correlate with individual variation in glycemic response to GLP-1RA therapy. Six hundred twenty participants with type 2 diabetes and hemoglobin A1c (HbA1c) ≥7.5 percent commencing GLP-1RA therapy were studied prospectively and their response to therapy was assessed over six months.

The researchers observed a correlation between reduced glycemic response to GLP-1RAs and longer duration diabetes, insulin cotreatment, lower fasting C-peptide, lower post-meal urine C-peptide-to-creatinine ratio, and positive GAD or IA2 islet autoantibodies (all P ≤ 0.01). Markedly reduced glycemic response to GLP-1RA therapy was seen for participants with positive autoantibodies (mean HbA1c change, −0.5 versus −1.4 percent; P = 0.005) or severe insulin deficiency (C-peptide <0.25 nmol/L, mean change −0.2 versus −1.4 percent; P = 0.002). These markers were mainly seen in insulin-treated participants and did not correlate with weight change.

"Clinical markers of low β-cell function are associated with reduced glycemic response to GLP-1RA therapy," the authors write. "C-peptide and islet autoantibodies represent potential biomarkers for the stratification of GLP-1RA therapy in insulin-treated diabetes."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths